December 1, 2020 5:09pm

Vaccine news has further buoyed spirits with several airlines making delivery to geographic localities for tiered groups

Pre-open indication results: 6 HITs and 2 MISS

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I track the numbers, so there’s no question re my opinion; so, you can do what others can't.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  


The Dow closed UP +185.28 points (+0.63%); the S&P closed UP +40.82 points (+1.13%) while the Nasdaq closed UP +156.37 points (+1.28%)

 

Henry’omics:

Indexes jumped on Tuesday as the market’s historic rally extended.

 

Pre-open indication: 6 HITs < BUY: Ionis Pharmaceuticals (IONS +$0.59); SELL into Strength: Fate Therapeutics (FATE +$1.76), Pluristem (PSTI -$0.13), Verastem Oncology (VSTM +$0.08), Intellia Therapeutics (NTLA -$1.17, Mesoblast (MESO +$0.03)> and 2 MISS <Global Blood Therapeutics (GBT +$2.27); Negligible: Biostage (BSTG +$0.01 with 902 shares traded)>

 

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: sector’s continued strength comes down to three things: movement of “weighting” versus “resistance” and vaccine news … https://www.regmedinvestors.com/articles/11657

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Tuesday opened positive at 20/12 and 4 flats, stayed positive at the mid-day at 22/12 and 1 flats, closing positive at 20/15 and 1 flat;
  • Monday opened negative at 13/20 and 2 flats, strayed neutral at the mid-day at 16/16 and 3 flats, closing positive at 21/13 and 1 flat;

 

Key metrics:

  • Sector volume was INCREASING with 10 of the 20-upside having higher than the 3-month average volume with the increased volume of 5 of 15-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 20-upside were +0.20% (MESO) to +8.56% (AGTC) while the 15-downside ranges from -0.09% (BCLI) to -12.47% (BLCM);

 

Hammered in today’s market:

  • ReNeuron (RENE.L), Intellia Therapeutics (NTLA), Sage Therapeutics (SAGE), BioLife Solutions (BLFS), Bellicum Pharmaceuticals (BLCM) to name 5 of the 15 declining of the 35 covered

Jumping with share pricing momentum:  

  • CRSP Therapeutics (CRSP), Alnylam Pharmaceuticals (ALNY), Global Blood therapeutics (GBT), Regenxbio (RGNX), uniQure NV (QURE) to name 5 of the 20 inclining of the 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +0.23% and XBI closed down -0.20%
  • Monday, the IBB closed up +0.35 % and XBI closed up +0.27%

 

Tuesday’s (10 of 20) incliners:

  • CRISPR Therapeutics (CRSP +$2.66 after Monday’s +$5.370;
  • Alnylam Pharmaceuticals (ALNY +$2.36);
  • Global Blood Therapeutics (GBT +$2.27 after Monday’s +$1.05);
  • bluebird bio (BLUE +$1.78);
  • Fate Therapeutics (FATE +$1.85 after Monday’s +$0.55);
  • uniQure NV (QURE +$1.65 after Monday’s -$1.01);
  • Regenxbio (+$1.63 after Monday’s -$2.10);
  • Cellectis SA (CLLS +$1.47 after Monday’s +$1.16);
  • Editas Medicine (EDIT +$1.31 after Monday’s -$0.75);
  • Ionis Pharmaceuticals (IONS +$0.59 after Monday’s -$0.60);

Tuesday’s (10 of 15) decliner:

  • ReNeuron (RENE.L -$4.00 after Monday’s +$2.50);
  • Sage Therapeutics (SAGE -$1.45 after Monday’s -$1.48);
  • Intellia Therapeutics (NTLA -$1.17 after Monday’s -$0.11);
  • Ultragenyx (RARE-$1.16 after Monday’s -$3.88
  • BioLife Solutions (BLFS -$1.00);
  • Bellicum Pharmaceuticals (BLCM -$0.46 after Monday’s +$0.50);
  • Chinook Therapeutics (KDNY -$0.34 after Monday’s -$0.02);
  • Pluristem (PSTI -$0.13 after Monday’s +$0.53);
  • Voyager therapeutics (VYGR -$0.12 after Monday’s -$0.14);
  • Athersys (ATHX -$0.06 after Monday’s -$0.05);

Closing 1 -Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Tuesday’s percentage (%) of the 20-upside were +0.20% (MESO) to +8.56% (AGTC) while the 15-downside ranges from -0.09% (BCLI) to -12.47% (BLCM);
  • Monday’s percentage (%) of the 21-upside were +0.04% (ALNY) to +15.67% (BCLM) while the 13- downside of -0.14% (KDNY) to -5.96% (RGNX);

 

Sentiment and a few daily indicators:

Sentiment got a lift after a group of lawmakers unveiled a $908 billion stimulus plan, which includes more than $200 billion in Paycheck Protection Program small business loans. The news gave stocks a boost, and pushed the 10-year Treasury yield above 0.9%. <CNBC>

Infection cases <Million>:

  • Tuesday 13.54 M cases
  • Monday 13.38 M cases

Tuesday’s death rate totaled 268,129 after Monday’s 266,887, Friday’s 263,525, Thursday was not recorded and Wednesday rate was 260,190 and last Tuesday’s 257,991. <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Tuesday: 10 out of the 20-upside had higher than the 3-month average volume;
  • Monday: 12 out of the 21-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.20 points or +0.97% at 20.77
  • Monday was down -0.27 points or -1.30% at 20.57

Downside volume:

  • Tuesday: 5 out of the 15-downside had higher than the 3-month average volume;
  • Monday: 9 out of the 13-downside had higher than the 3-month average volume;

 

December, the 3rd month of Q4 …

Tuesday (12/1) closed positive with 20 advancers, 15 decliners and 1 flat 

 

The Bottom Line: the sector followed the market, that does NOT mean it will be SUSTAINABLE!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.